Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Conditions: Rectal Adenocarcinoma; Circulating Tumor DNA; Minimal Residual Disease; Neoadjuvant Chemoradiotherapy Intervention: Diagnostic Test: MRD detection Sponsors: WeiWei Xiao; Haplox Biotechnology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials